Your browser doesn't support javascript.
loading
Cost-utility analysis of pharmacogenomics-guided tacrolimus treatment in Austrian kidney transplant recipients participating in the U-PGx PREPARE study.
Fragoulakis, Vasileios; Koufaki, Margarita-Ioanna; Joefield-Roka, Candace; Sunder-Plassmann, Gere; Mitropoulou, Christina.
Afiliación
  • Fragoulakis V; The Golden Helix Foundation, London, UK.
  • Koufaki MI; Department of Pharmacy, Laboratory of Pharmacogenomics and Individualized Therapy, University of Patras, School of Health Sciences, Patras, Greece.
  • Joefield-Roka C; Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.
  • Sunder-Plassmann G; Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.
  • Mitropoulou C; The Golden Helix Foundation, London, UK. c.mitropoulou@goldenhelix.org.
Pharmacogenomics J ; 24(2): 10, 2024 Mar 18.
Article en En | MEDLINE | ID: mdl-38499549
ABSTRACT
Chronic kidney disease (CKD) is a global health issue. Kidney failure patients may undergo a kidney transplantation (KTX) and prescribed an immunosuppressant medication i.e., tacrolimus. Tacrolimus' efficacy and toxicity varies among patients. This study investigates the cost-utility of pharmacogenomics (PGx) guided tacrolimus treatment compared to the conventional approach in Austrian patients undergone KTX, participating in the PREPARE UPGx study. Treatment's effectiveness was determined by mean survival, and utility values were based on a Visual Analog Scale score. Incremental Cost-Effectiveness Ratio was also calculated. PGx-guided treatment arm was found to be cost-effective, resulting in reduced cost (3902 euros less), 6% less hospitalization days and lower risk of adverse drug events compared to the control arm. The PGx-guided arm showed a mean 0.900 QALYs (95% CI 0.862-0.936) versus 0.851 QALYs (95% CI 0.814-0.885) in the other arm. In conclusion, PGx-guided tacrolimus treatment represents a cost-saving option in the Austrian healthcare setting.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Trasplante de Riñón / Tacrolimus Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Pharmacogenomics J Asunto de la revista: BIOLOGIA MOLECULAR / FARMACOLOGIA Año: 2024 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Trasplante de Riñón / Tacrolimus Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Pharmacogenomics J Asunto de la revista: BIOLOGIA MOLECULAR / FARMACOLOGIA Año: 2024 Tipo del documento: Article